Cargando…
Partial nephrectomy for metastatic renal cell carcinoma: Where do we stand?
Nephron-sparing surgery (NSS) for renal cell carcinoma (RCC) offers comparable oncologic results, but a lower risk of chronic kidney disease, when compared with radical nephrectomy. However, there are limited data in the literature examining the safety of NSS in the setting of metastatic RCC. To eva...
Autores principales: | Shahait, Mohammed, Mukherji, Deborah, El-Hout, Yaser |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4397543/ https://www.ncbi.nlm.nih.gov/pubmed/25878408 http://dx.doi.org/10.4103/0970-1591.154300 |
Ejemplares similares
-
Renal denervation – where do we stand in 2014?
por: Januszewicz, Andrzej, et al.
Publicado: (2014) -
Where Do We Stand?
Publicado: (1891) -
The Role of Circulating Biomarkers in the Oncological Management of Metastatic Renal Cell Carcinoma: Where Do We Stand Now?
por: Cinque, Alessandra, et al.
Publicado: (2021) -
Hepatocellular Carcinoma in Pakistan: Where do We Stand?
por: Butt, Amna Subhan, et al.
Publicado: (2012) -
Gravity: where do we stand ?
por: Peron, Roberto, et al.
Publicado: (2016)